QURE has been in the news 409% more than usual
Feb 23, 2026, 7:33 AM
-34.84%
What does QURE do
uniQure NV, headquartered in Amsterdam, specializes in gene therapies and employs 480 staff, focusing on one-time treatments for genetic diseases. Their lead candidates include AMT-061 for hemophilia B and AMT-130 for Huntington's disease.
QURE has been in the news recently: Rosen Law, DJS Law Group, and the Schall Law Firm have filed or announced class actions against uniQure N.V., alleging false statements and securities fraud related to purchases of QURE shares between September 24 and October 31, 2025. Investors who bought QURE during that period have until April 13, 2026 to file a claim or join the litigation.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.